Monday was quite the day for biotech companies developing the next generation of obesity drugs. One of them, Structure ...

The biotech's investigational weight loss drug did very well in a clinical trial. This is a white-hot segment of the pharmaceutical market, so it's little wonder investors subsequently pounced on the ...

Recursion Pharmaceuticals (NASDAQ: RXRX) was in the headlines on Monday, and for the right reason. One of the biotech company's investigational drugs did well in a clinical trial, and investors ...

The ASH meeting included positive early results about a Terns drug for chronic myeloid leukemia and a Kura menin-blocker for ...

Data from Structure Therapeutics and WAVE Life Sciences show that threats to Eli Lilly and Novo Nordisk’s dominance in weight ...

Precise Bio Inc., a Greensboro-based clinical-stage regenerative medicine company, has announced the world’s first transplant ...

Ohio-based Welltower acquired adjacent senior housing centers for a total of $140M, the Boston Business Journal reported. The ...

As of Monday, December 08, Legend Biotech Corporation’s LEGN share price has dipped by 8.82%, which has investors questioning if this is right time to buy.

The CEO foresees a "snowball effect" of life sciences companies coming to Dallas, but a couple things need to happen first.

As AI reshapes biotechnology, stakeholders are acting to establish governance to maintain safety and efficacy standards.

Provost Ibba described Chapman as a community defined by its willingness to come together across disciplines, whether in the ...

With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli ...